1. Market Research
  2. > Biotechnology
  3. > Biopharmaceutical Market Trends
  4. > Canopus BioPharma Incorporated - Product Pipeline Review - 2013

Canopus BioPharma Incorporated - Product Pipeline Review - 2013

  • August 2013
  • -
  • Global Markets Direct
  • -
  • 33 pages

Canopus BioPharma Incorporated - Product Pipeline Review - 2013

Summary

Global Market Direct’s pharmaceuticals report, “Canopus BioPharma Incorporated - Product Pipeline Review - 2013” provides data on the Canopus BioPharma Incorporated’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Canopus BioPharma Incorporated’s corporate website, SEC filings, investor presentations and featured press releases, both from Canopus BioPharma Incorporated and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Canopus BioPharma Incorporated - Brief Canopus BioPharma Incorporated overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Canopus BioPharma Incorporated human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Canopus BioPharma Incorporated with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Canopus BioPharma Incorporated’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Canopus BioPharma Incorporated’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Canopus BioPharma Incorporated in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Canopus BioPharma Incorporated’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Canopus BioPharma Incorporated.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Canopus BioPharma Incorporated and identify potential opportunities in those areas.

Table Of Contents

Canopus BioPharma Incorporated - Product Pipeline Review - 2013
Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Canopus BioPharma Incorporated Snapshot 5
Canopus BioPharma Incorporated Overview 5
Key Information 5
Key Facts 5
Canopus BioPharma Incorporated - Research and Development Overview 6
Key Therapeutic Areas 6
Canopus BioPharma Incorporated - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
Pipeline Products - Combination Treatment Modalities 11
Canopus BioPharma Incorporated - Pipeline Products Glance 12
Canopus BioPharma Incorporated Clinical Stage Pipeline Products 12
Phase II Products/Combination Treatment Modalities 12
Canopus BioPharma Incorporated - Early Stage Pipeline Products 13
Preclinical Products/Combination Treatment Modalities 13
Discovery Products/Combination Treatment Modalities 14
Canopus BioPharma Incorporated - Drug Profiles 15
Antibacterial Agent 15
Product Description 15
Mechanism of Action 15
RandD Progress 15
CB-1600 16
Product Description 16
Mechanism of Action 16
RandD Progress 16
CB-1922 17
Product Description 17
Mechanism of Action 17
RandD Progress 17
CB-2009 18
Product Description 18
Mechanism of Action 18
RandD Progress 18
CB-2029 19
Product Description 19
Mechanism of Action 19
RandD Progress 19
CB-2030 20
Product Description 20
Mechanism of Action 20
RandD Progress 20
CB-3900 21
Product Description 21
Mechanism of Action 21
RandD Progress 21
CB-4500 22
Product Description 22
Mechanism of Action 22
RandD Progress 22
CB-5300 23
Product Description 23
Mechanism of Action 23
RandD Progress 23
oltipraz 24
Product Description 24
Mechanism of Action 24
RandD Progress 24
Canopus BioPharma Incorporated - Pipeline Analysis 25
Canopus BioPharma Incorporated - Pipeline Products by Therapeutic Class 25
Canopus BioPharma Incorporated - Pipeline Products By Target 27
Canopus BioPharma Incorporated - Pipeline Products by Route of Administration 28
Canopus BioPharma Incorporated - Pipeline Products By Mechanism of Action 29
Canopus BioPharma Incorporated - Dormant Projects 30
Canopus BioPharma Incorporated - Locations And Subsidiaries 31
Head Office 31
Other Locations and Subsidiaries 31
Appendix 32
Methodology 32
Coverage 32
Secondary Research 32
Primary Research 32
Expert Panel Validation 32
Contact Us 33
Disclaimer 33



List of Tables

Canopus BioPharma Incorporated, Key Information 5
Canopus BioPharma Incorporated, Key Facts 5
Canopus BioPharma Incorporated - Pipeline by Indication, 2013 8
Canopus BioPharma Incorporated - Pipeline by Stage of Development, 2013 9
Canopus BioPharma Incorporated - Monotherapy Products in Pipeline, 2013 10
Canopus BioPharma Incorporated - Combination Treatment Modalities in Pipeline, 2013 11
Canopus BioPharma Incorporated - Phase II, 2013 12
Canopus BioPharma Incorporated - Preclinical, 2013 13
Canopus BioPharma Incorporated - Discovery, 2013 14
Canopus BioPharma Incorporated - Pipeline By Therapeutic Class, 2013 26
Canopus BioPharma Incorporated - Pipeline By Target, 2013 27
Canopus BioPharma Incorporated - Pipeline By Route of Administration, 2013 28
Canopus BioPharma Incorporated - Pipeline Products By Mechanism of Action, 2013 29
Canopus BioPharma Incorporated - Dormant Developmental Projects,2013 30
Canopus BioPharma Incorporated, Other Locations 31



List of Figures

Canopus BioPharma Incorporated - Pipeline by Indication, 2013 7
Canopus BioPharma Incorporated - Pipeline by Stage of Development, 2013 9
Canopus BioPharma Incorporated - Monotherapy Products in Pipeline, 2013 10
Canopus BioPharma Incorporated - Combination Treatment Modalities in Pipeline, 2013 11
Canopus BioPharma Incorporated - Pipeline By Therapeutic Class, 2013 25
Canopus BioPharma Incorporated - Pipeline By Route of Administration, 2013 28
Canopus BioPharma Incorporated - Pipeline Products By Mechanism of Action, 2013 29



Companies Mentioned

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Galena Biopharma, Inc. (GALE) - Financial and Strategic SWOT Analysis Review

Galena Biopharma, Inc. (GALE) - Financial and Strategic SWOT Analysis Review

  • $ 300
  • Company report
  • October 2016
  • by Global Data

Summary Galena Biopharma, Inc. (Galena) is a biotechnology company that discovers, develops and commercializes therapies for the treatment of unmet medical needs, and advance care. Its pipeline products ...

ARCA biopharma, Inc. (ABIO) - Financial and Strategic SWOT Analysis Review

ARCA biopharma, Inc. (ABIO) - Financial and Strategic SWOT Analysis Review

  • $ 300
  • Company report
  • October 2016
  • by Global Data

Summary ARCA biopharma, Inc. (ARCA), formerly Nuvelo, Inc., is a biopharmaceutical company. The company focuses on the development of genetically targeted therapies for cardiovascular diseases. Its product ...

Can-Fite BioPharma Ltd. (CFBI) - Financial and Strategic SWOT Analysis Review

Can-Fite BioPharma Ltd. (CFBI) - Financial and Strategic SWOT Analysis Review

  • $ 300
  • Company report
  • October 2016
  • by Global Data

Summary Can-Fite BioPharma Ltd. (Can-Fite) is a biopharmaceutical company that concentrates on the discovery and clinical development of drugs. The company's pipeline product portfolio comprise CF101, ...


ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.